Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.32 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.31 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768868 | 0.81 | SMPD3 (0.42) | SMPD3HSP90AA1SRCSYKPDE10A | |
| SCHEMBL24656216 | 0.79 | ADORA3 (0.45) | ADORA2AADORA1ADORA3SMPD3PDE11A | |
| SCHEMBL16482533 | 0.74 | SMPD3 (0.33) | SMPD3HSP90AA1SYKRAB9A | |
| SCHEMBL20659411 | 0.68 | GAA (0.41) | ADORA2AALDH1A1ADORA2B | |
| SCHEMBL13541623 | 0.66 | ADORA3 (0.43) | ADORA2AADORA1ADORA3PDE11AHSP90AA1 | |
| SCHEMBL16463680 | 0.65 | STIM1 (0.43) | ADORA2AADORA1ADORA3KMT2ASYK | |
| SCHEMBL3187006 | 0.64 | ADORA2A (0.31) | ADORA2AADORA2B | |
| SCHEMBL21241203 | 0.64 | PDE10A (0.40) | ADORA2AADORA1SMPD3HSP90AA1SRC | |
| SCHEMBL723295 | 0.63 | LMNA (0.40) | HPGDSTIM1ORAI1 | |
| SCHEMBL26639107 | 0.62 | KDM4E (0.44) | ADORA2AADORA1SMPD3ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | DRAIG THERAPEUTICS LTD (GB) | 2024-12-26 | — | — | US | disclosed |
| EP-4334301-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | University College Cardiff Consultants Limited (GB) | 2024-03-13 | — | — | EP | disclosed |
| CN-117279908-A | Heteroaryl compounds for the treatment of cognitive disorders | 加的夫大学学院咨询有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2022234271-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9512116-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512116-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-09-03 | — | — | US | disclosed |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-09-03 | — | — | US | disclosed |
| WO-2014059333-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ADORA2A 1775/4885ADORA1 2226/4885ADORA3 2617/4885 |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | GABRA5, GABRB3, GABRA3 | ADORA2A 236/4885ADORA1 239/4885ADORA3 153/4885 |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ADORA2A 1775/4885ADORA1 2226/4885ADORA3 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.